<DOC>
	<DOCNO>NCT02204683</DOCNO>
	<brief_summary>The main goal study way aflibercept injection behaves eye body patient wet macular degeneration , patient previous vitreous removal surgery .</brief_summary>
	<brief_title>A Pharmacokinetic Study Intravitreal Aflibercept Injection Vitrectomized Non-vitrectomized Eyes With Wet Age-related Macular Degeneration ( DRAW ) .</brief_title>
	<detailed_description>A pharmacokinetic study intravitreal Aflibercept injection vitrectomized non-vitrectomized eye Wet age-related macular degeneration ( DRAW study ) . The primary objective investigate characterize intraocular pharmacokinetics intravitreal aflibercept injection vitrectomized non-vitrectomized eye neovascular Age-related Macular Degeneration ( AMD ) . The secondary objective ass systemic pharmacokinetics intravitreal aflibercept injection . Little information know intraocular pharmacokinetics intravitreal aflibercept injection human eye . In addition , durability intravitreal aflibercept injection vitrectomized eye know , since individual history vitrectomy exclude clinical trial neovascular AMD . There also study systemic level follow intravitreal aflibercept injection , would implications normal vascular hemostasis wound repair vascular endothelial growth factor ( VEGF ) play important role . The propose research fill gap knowledge base intravitreal aflibercept injection . Two arm ( non-vitrectomized , vitrectomized ) include study evaluate intraocular systemic pharmacokinetics intravitreal aflibercept injection The study involve neovascular AMD patient divide two group : 5 patient history vitrectomy 10 patient history vitrectomy . Plasma blood aqueous fluid collect baseline , 2mg intravitreal aflibercept injection administer time 0 ( day 0 ) . At 4 hour post injection , plasma ( blood ) aqueous fluid collect , well day 1 , 3 , 7,14 , 28 . Intravitreal aflibercept injection level sample assess compare among two group .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>1 . Age &gt; 50 year 2 . Active neovascular AMD , history treatment study eye 2.1 10 patient nonvitrectomized eye 2.2 5 patient vitrectomized eye 3 . Phakic pseudophakic eye allow study . 4 . Willing able provide write informed consent nature study explain , prior researchrelated procedure 5 . Willing able comply clinic visit studyrelated procedure 1 . Presence retinal vascular disease ( diabetic retinopathy , vein occlusion ) could affect VEGF level within eye 2 . Known hypersensitivity aflibercept 3 . Autoimmune disease anterior segment posterior chamber include chronic keratoconjunctivitis sicca , uveitis , iritis/scleritis , blepharitis either eye 4 . Infectious conjunctivitis , keratitis , endophthalmitis either eye 5 . Previous participation study investigational drug within 1 month precede Day 0 6 . Any clinically significant acute chronic medical condition would preclude participation clinical study 7 . Pregnant breastfeed woman 8 . Sexually active men* woman childbearing potential** unwilling practice adequate contraception study ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device ( IUD ) ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly ) *Contraception require men document vasectomy . **Postmenopausal woman must amenorrheic least 12 month order consider child bear potential . Pregnancy test contraception require woman document hysterectomy tubal ligation .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>AMD</keyword>
	<keyword>Neovascularization</keyword>
	<keyword>macular degeneration</keyword>
	<keyword>wet macular degeneration</keyword>
	<keyword>vitrectomy</keyword>
</DOC>